Document ID: FDA-2021-N-0834-0001
Agency: fda
Document Type: Notice
Title: Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments
Posted Date: 2021-08-10T04:00Z

[Federal Register Volume 86, Number 151 (Tuesday, August 10, 2021)]
[Notices]
[Pages 43667-43669]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17041]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-N-0834]

Post-Marketing Pediatric-Focused Product Safety Reviews; 
Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is establishing a 
public docket to collect comments related to the post-marketing 
pediatric-focused safety reviews of products posted between September 
2, 2020, and September 2, 2021, on FDA's website but not presented at 
the September 17, 2021, Pediatric Advisory Committee (PAC) meeting. 
These reviews are intended to be available for review and comment by 
members of the PAC, interested parties (such as academic researchers, 
regulated industries, consortia, and patient groups), and the general 
public.

DATES: Submit either electronic or written comments by September 24, 
2021.

ADDRESSES: FDA is establishing a docket for public comment on this 
document. The docket number is FDA-2021-N-0834. The docket will close 
on September 24, 2021. Submit either electronic or written comments by 
that

[[Page 43668]]

date. Please note that late, untimely comments will not be considered. 
Electronic comments must be submitted on or before September 24, 2021. 
The https://www.regulations.gov electronic filing system will accept 
comments until 11:59 p.m. Eastern Time at the end of September 24, 
2021. Comments received by mail/hand delivery/courier (for written/
paper submissions) will be considered timely if they are postmarked or 
the delivery service acceptance receipt is on or before that date.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2021-N-0834 for ``Post-Marketing Pediatric-Focused Product Safety 
Reviews; Establishment of a Public Docket; Request for Comments.'' 
Received comments, those filed in a timely manner (see ADDRESSES), will 
be placed in the docket and, except for those submitted as 
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. 
and 4 p.m., Monday through Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review 
this copy, including the claimed confidential information, in its 
consideration of comments. The second copy, which will have the claimed 
confidential information redacted/blacked out, will be available for 
public viewing and posted on https://www.regulations.gov. Submit both 
copies to the Dockets Management Staff. If you do not wish your name 
and contact information be made publicly available, you can provide 
this information on the cover sheet and not in the body of your 
comments and you must identify the information as ``confidential.'' Any 
information marked as ``confidential'' will not be disclosed except in 
accordance with 21 CFR 10.20 and other applicable disclosure law. For 
more information about FDA's posting of comments to public dockets, see 
80 FR 56469, September18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Marieann Brill, Office of the 
Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 32, Rm. 5154, Silver Spring, MD 20993, 240-402-3838, 
marieann.brill@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is responsible for protecting the public 
health by assuring the safety, efficacy, and security of human and 
veterinary drugs, biological products, medical devices, our Nation's 
food supply, cosmetics, and products that emit radiation. FDA also has 
responsibility for regulating the manufacturing, marketing, and 
distribution of tobacco products to protect the public health and to 
reduce tobacco use by minors.
    FDA is establishing a public docket, Docket No. FDA-2021-N-0834, to 
receive input on post-marketing pediatric-focused safety reviews of 
products posted between September 2, 2020, and September 2, 2021, 
available on FDA's website at https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ucm510701.htm but 
not presented at the September 17, 2021, PAC meeting. FDA welcomes 
comments by members of the PAC, as mandated by the Best Pharmaceuticals 
for Children Act (Pub. L. 107-109) and the Pediatric Research Equity 
Act of 2003 (Pub. L. 108-155), interested parties (such as academic 
researchers, regulated industries, consortia, and patient groups), and 
the general public. The docket number is FDA-2021-N-0834. The docket 
will open on September 3, 2021, and remain open until September 24, 
2021. The post-marketing pediatric-focused safety reviews are for the 
following products from the following centers at FDA:

Center for Biologics Evaluation and Research

1. CUVITRU (immune globulin subcutaneous (human), 20 percent solution)
2. EPICEL (cultured epidermal autografts)
3. JIVI (antihemophilic factor (recombinant), PEGylated-aucl)
4. T.R.U.E. TEST (thin-layer rapid use epicutaneous patch test)
5. REBINYN (nonacog beta pegol (N9-GP))
6. RUBBER PANEL T.R.U.E. TEST (Rubber Panel thin-layer rapid use 
epicutaneous patch test)
7. ROTATEQ (Rotavirus vaccine, live, oral, pentavalent)

Center for Drug Evaluation and Research

1. APTIOM (eslicarbazepine acetate)
2. CIALIS (tadalafil)
3. COTEMPLA XR-ODT (methylphenidate extended release orally 
disintegrating tablets)
4. EMEND (fosaprepitant dimeglumine)
5. ENBREL (etanercept), ERELZI (etanercept-szzs), ETICOVO (etanercept-
ykro)
6. FASENRA (benralizumab)
7. INTELENCE (etravirine)
8. PEGASYS (peginterferon alfa-2a)

[[Page 43669]]

9. TEKTURNA (aliskiren hemifumarate)
10. VIMOVO (naproxen/esomeprazole magnesium)
11. VIREAD (tenofovir disoproxil fumarate)
12. XOFLUZA (baloxavir marboxil)

Center for Devices and Radiological Health

1. CONTEGRA PULMONARY VALVED CONDUIT (Humanitarian Device Exemption 
(HDE))
2. ELANA SURGICAL KIT (HDE)
3. ENTERRA THERAPY SYSTEM (HDE)
4. LIPOSORBER LA-15 SYSTEM (HDE)
5. MEDTRONIC ACTIVA DYSTONIA THERAPY (HDE)
6. MINIMALLY INVASIVE DEFORMITY CORRECTION (MID-C) SYSTEM
7. PLEXIMMUNE IN-VITRO DIAGNOSTIC TEST (HDE)
8. PULSERIDER ANEURYSM NECK RECONSTRUCTION DEVICE (HDE)
9. THE TETHER--VERTEBRAL BODY TETHERING SYSTEM

    Dated: August 5, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-17041 Filed 8-9-21; 8:45 am]
BILLING CODE 4164-01-P